Seach Medical Group Ltd.

Investor Presentation • Sep 5, 2022

Seach Medical Group - Investors deck - 2022 Q2

August 2022

1

Legal Disclaimer

Clarification: This Company's Investors Deck (the "Presentation") includes general and partial information only, and should be read in conjunction with the Company's immediate and periodic reports published from time to time (the "Company's Reports "), including its financial statements attached to the Company's Periodic Report for the year 2021, dated March 21, 2022, its Periodic Report for first quarter of 2022 dated May 30, 2022 and its Periodic Report for second quarter of 2022 dated August 23, 2022 (Reference No.: 2022-01-032011, 2022-01-054000 and 2022-01-107020 respectively) (the "Periodic Reports"). In any event of discrepancy or inconsistency between the information specified in this Presentation and the information appearing in the Company's Reports or the Periodic Report, the latter shall prevail, as the case may be.

This Presentation does not constitute an offer to purchase or sell securities or an invitation to receive such offers and is intended to provide information only. The information does not constitute a recommendation or opinion nor does it constitute a substitute for the discretion or collection and analysis of independent and additional information of any potential investor. The images shown in this presentation are for illustration purposes only.

The information in the presentation does not relate to the specific considerations or requirements of any potential investor or to legal, accounting, tax, regulatory and other aspects related to the investment by such investor. In any event this Presentation does not constitute any advice or guidance. It does not constitute a substitute for the receipt of professional advice and guidance by a person authorized to give it. Every potential investor should seek such advice and guidance in connection with his potential investment, including tax consultation that takes into consideration his data and tax status.

The Presentation includes plans for operations and/or moves and/or evaluations of the Company based on the Company's operations as of today, that constitutes forward-looking information, as the term is defined in the Securities Law, 5728-1968, including forecasts, business goals, evaluations and standards, and any other information, in any manner provided, relating to the future events or matters, the realization of which is uncertain and not under the Company's control. The realization and/or non-realization of the forward-looking information as stated can be affected by risk factors that characterize the Company's operations, as well as developments in the economic environment and external factors that affect its operations, all as specified in the Company's Reports and Periodic Report. It is also clarified that the Company's plans and strategy included in this Presentation are correct as of the date of its publication and may change in accordance with the decisions of the Company's board of directors. For the removal of any doubt, it is clarified that the company does not undertake to update and/or change the information contained in the Presentation in order to reflect events and/or circumstances that will apply after the preparation of this Presentation.

Seach's Milestones 2008-2022

Quarterly Summary

2020 Q2 Highlights

• New quarterly revenue record of NIS 34.2 million 221% increase compared to the second quarter 2021. Accumulated 2022 revenue of NIS 64.9 million – 220% increase compared to 2021 first half.
• Quarterly adjusted EBITDA of NIS 5.9 million 288% increase compared to the second quarter 2021. Accumulated adjusted EBITDA of NIS 9.3 million – 168% increase compared to 2021 first half.
• NIS 7 million positive cashflow from operations.
• Acquisition of two pharmacies in Jerusalem in July 2022 while expanding the pharmacy chain to 5 branches.

^* Adjusted EBITDA: Operational income before depreciation and amortization, depreciation of intangible assets and amortization of inventory from first time consolidation, changes in fair market value of biological assets, share based compensation expenses, loss from disposal and decrease in holding stake in associates, IFRS 16, other (income) expenses.

New quarterly revenue record of NIS 34.2 million – 221% increase compared to the second

quarter 2021

Accumulated 2022 revenue of NIS 64.9 million – 220% increase compared to 2021 first half

* Assuming no significant changes in revenue growth during 2022 based on the first 2 quarters of 2022.

5

Adjusted EBITDA

Quarterly adjusted EBITDA of NIS 5.9 million – 288% increase compared to the second

quarter 2021

Accumulated 2022 adjusted EBITDA of NIS 9.3 million – 168% increase compared to 2021

first half

* Adjusted EBITDA: Operational income before depreciation and amortization, depreciation of intangible assets and amortization of inventory from first time consolidation, changes in fair market value of biological assets, share based compensation expenses, loss from disposal and decrease in holding stake in associates, IFRS 16, other (income) expenses.

Israeli Market Strategy

Pharmacy Chain

Seach controls 5 Cannabis-selling pharmacies

• During the second quarter of 2022 "Shefa" pharmacy in Tel-Aviv received license to sell medical Cannabis products
• In July 2022, Seach acquired control in "Mediplus" which operates two pharmacies in Jerusalem – expanding the pharmacy chain to 5 branches
• Seach intends to expand the pharmacy chain to 10 branches by the end of 2023

Kosher Cannabis

Traditional-Orthodox Market

Traditional-Orthodox Market

• Seach is committed to make the company's products accessible to new target audiences with an emphasis on the traditional-Orthodox market
• During April 2022 Seach received a "Kosher" certificate for most of its products (including "Shmita" certificate for our cultivation facilities)
• Seach is the first and only Israeli company to introduce Kosher medical Cannabis products to the Israeli market (including "Shmita" certificate)*

New products launch Diverse Products Portfolio

Export

Cannabis export from Israel

Seach is the largest Israeli Cannabis exporter*

• Seach is engaged in export of medical Cannabis products and bulk Cannabis inflorescence on regular basis to Australia and additional countries, directly and through joint-ventures

* To the best of company's knowledge

Strategy

Focus on the expanding Israeli Market

• Generating strong relationships with the Israeli clients through deep understanding of the clients' needs
• Building strong brands with diverse products portfolio
• Ongoing export to Australia and additional countries

Operational flexibility

• Holding the supply chain from both sides (from cultivation to expanding pharmacy chain)
• Expanding collaborations and jointventures through the supply chain with focus on quality

Financial flexibility

• To support the growth of Seach's activities
• To support local business opportunities
• To support potential M&A transactions with focus on profitable opportunities

Looking forward

• Seach expects continued growth in both wholesale & retail sales
• Seach to develop the pharmacy chain to 10 branches by the end of 2023 while increasing synergy within the group
• Preparation for CBD potential legislation
• Building infrastructure toward potential recreational legislation

Seach Medical Group - Investors deck - 2022 Q2

August 2022

www.seach.co.il

cfo@seach.co.il